3:20cv6719 • September 25, 2020
Class Period Start
March 3, 2020
Class Period End
November 16, 2020
PSLRA Deadline
November 24, 2020
Case Allegations
10b5
Statutes of Repose
Mar 3, 2023
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
October 30, 2023
Settlement Fund
$39,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased or otherwise acquired the common stock of BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) from March 3, 2020 through August 18, 2020, inclusive.
Claim Administrator
A.B. Data, Ltd.
BioMarin Securities Litigation
c/o A.B. Data, Ltd.
P.O. Box 170400
Milwaukee, WI 53217
+1 877-390-3369
[email protected]
Settlement Website
https://www.biomarinsecuritieslitigation.com/Hearing Date
November 8, 2023
Opt-out Deadline
October 18, 2023
Settlement Note
Download hereProof Of Claim
Download here
May 3, 2024
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Nov 14, 2023
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Jun 30, 2023
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Jun 8, 2023
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Apr 28, 2023
Oct 17, 2022
Motion for Class Certification
The plaintiffs have asked the court to approve the lawsuit to proceed as a class action on behalf of a group of investors. The judge will decide whether the case meets the requirements for class certification and which investors and claims may be included.
Jan 6, 2022
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Apr 22, 2021
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Feb 22, 2021
A new complaint has been filed on behalf of certain investors in BIOMARIN PHARMACEUTICAL INC. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Jan 7, 2021
Dec 22, 2020
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Sep 25, 2020
A securities fraud class action complaint has been filed on behalf of certain investors in BIOMARIN PHARMACEUTICAL INC.
TOP
